



Prediction of antibiotic resistance in *Escherichia coli* from resistance genes

Terry Walker¹, Julia Quan¹, Stephen G. Higgins¹, Nikhil Toraskar¹, Weizhong Chang¹, Kelsey Pitzer¹, Danyel Donovan¹, Lori Settle¹, Natalie Whitfield¹, Bert K. Lopansri² & Mary Motyl³

(1) OpGen, Inc., Gaithersburg MD, USA (2) Intermountain Medical Center, Murray, UT, USA, (3) Merck and Co. Inc., USA

Background: Phenotypic antimicrobial susceptibility testing (AST) is the standard guide for antibiotic use, but it takes days to perform. Molecular tests can rapidly detect resistance genes within hours of specimen collection, but they have not demonstrated comprehensive prediction of phenotypic antibiotic resistance.

Material/Methods: We compared PCR results for 126 resistance genes with phenotypic AST results across 1931 highly resistant clinical isolates of *E. coli* including 1366 ESBLs collected at the Intermountain Medical Center over 2008 to 2015 plus 565 *E. coli* isolates from Merck's SMART Surveillance Network as supplied by International Health Management Associates. Statistical models were used to predict antibiotic resistance from resistance genes.

Results: We identified a panel of critical resistance genes and developed statistical algorithms to accurately predict phenotypic resistance for several antibiotics across 1931 highly resistant clinical isolates of *E. coli*. The study demonstrates rapid genotypic prediction of resistance for 17 antibiotics representing 7 antibiotic classes as comprehensive information toward antibiotic options against a spectrum of resistance. Future studies will improve prediction of carbapenem resistance through evaluation of more *E. coli* isolates.

Conclusions: Molecular detection of resistance genes offers the potential to predict antibiotic resistance days ahead of phenotypic AST for Gram-negative bacteria toward better patient and hospital management.

Genotypic prediction of phenotypic non-susceptibility for 1931 *E. coli* isolates

Antibiotic Class	Antibiotic	Accuracy %	Sensitivity %	Specificity %	PPV %	NPV %	
Aminoglycosides	Tobramycin	90	91	88	90	90	
	Gentamicin	91	87	94	89	92	
Carbapenems	Ertapenem	90	52	94	45	95	
	Imipenem	94	55	96	46	97	
	Meropenem	97	58	98	49	99	
	Cefazolin	88	90	73	97	44	
Cephalosporins	Cefuroxime	90	91	76	97	52	
	Ceftriaxone	92	94	79	97	66	
	Cefotaxime	89	91	79	96	61	
	Cefepime	88	92	72	92	70	
	Ceftazidime	77	81	73	81	73	
	Penicillins	Ampicillin	95	96	71	99	43
		Piperacillin	94	95	76	99	48
Fluroquinolones	Ciprofloxacin	93	95	85	96	83	
	Levofloxacin	93	95	87	96	85	
Macrolides	Tetracycline	92	94	89	95	87	
Co-trimoxazoles	Trimeth/Sulfa	89	93	83	91	86	

